

From: Robert Lodge <Robert.Lodge@state.co.us> **Date:** Friday, August 4, 2017 at 3:49 PM **To:** Robert Lodge <Robert.Lodge@state.co.us> **Subject:** PDL Preferred Products Announcement - CO Medicaid

Good afternoon everyone,

The following drug classes and their preferred agents will become effective October 1, 2017. The Drug Utilization Review Board meeting will be held on August 15, 2017, to discuss prior authorization criteria for these classes of drugs.

Oral Anticoagulants: warfarin, Xarelto and Pradaxa

Bisphosphonates: alendronate tablets

Amylin: no preferred

Biguanides: metformin IR, metformin XR 500mg (generic Glucophage XR)

Hypoglycemic Combinations: no preferred

Meglitinides: no preferred

DPP4 Inhibitors: Tradjenta

GLP1 Receptor Agonists: Byetta and Bydureon preferred first line, Victoza

SGLT2 Inhibitors: Invokana and Farxiga

Thiazolidinediones: pioglitazone

Erythropoiesis Stimulating Agents: Epogen

Overactive Bladder Agents: oxybutynin tablets, oxybutynin ER tablets, Toviaz

Stimulants and ADHD: Adderall IR (brand and generic), Amphetamine/Dextroamphetamine XR (generic Adderall XR), Focalin IR (brand only), Focalin XR (brand only), Guanfacine ER (generic Intuniv), Ritalin IR (brand and generic), Concerta (brand only), Strattera (brand only), Vyvanse capsules

Hepatitis C Agents:

- **Genotype 1:** Viekira XR/Pak (Harvoni for decompensated cirrhosis)
- **Genotypes 2 and 3:** Epclusa
- **Genotype 4:** Technivie

Genotypes 5 and 6: no preferred

Colony Stimulating Factors: Neupogen vial

GI Motility Agents: Amitiza, Linzess, Movantik

Ophthalmic Immunomodulators: Restasis (single-dose)

Thank you,

Robert Lodge, PharmD
Drug Utilization Review Pharmacist



P 303.866.3105 | F 303.866.3590
1570 Grant Street, Denver, CO 80203
robert.lodge@state.co.us | Colorado.gov/hcpf